| Betagan (U.S.N.L.M.) | |
|---|---|
| Dosing | 0.5%: 1 or 2 drops qAM to start, bid max. 0.25%: 1 or 2 drops bid. |
| Chem Specs | levobunolol HCL 0.25%, 0.5% |
| Quantities | 5, 10, 15ml (0.5%) 10, 15ml (0.25%) |
| Cost | 24.75/5ml 0.5% generic |
| Class | Noncardioselective Beta-Blocker |
| Action | Ocular hypotensive via decrease in aqueous humor production. |
| Usage | Indicated for lowering IOP with chronic open-angle glaucoma or ocular hypertension. |
| Evaluate blood pressure, pulse, neurological and respiratory status before and during treatment. Evaluate blood pressure, pulse, neurological and respiratory status before and during treatment. |
|
| Contraindications | Asthma, COPD, bradycardia and/or congestive heart failure, uncontrolled diabetes and hyperlipidemia. Asthma, COPD, bradycardia and/or congestive heart failure, uncontrolled diabetes and hyperlipidemia. |
| Pediatric use | Safety and effectiveness in pediatric patients have not been established. |
| Pregnancy | Category C. Fetotoxicity demonstrated in rabbits but not replicated in rats. |
| Longest half-life of the topical beta-blockers. Dosages above 1 drop 0.5% bid are generally not more effective. Studies support 1 drop 0.25% qd for some. 0.004% BAK preserved. Longest half-life of the topical beta-blockers. Dosages above 1 drop 0.5% bid are generally not more effective. Studies support 1 drop 0.25% qd for some. 0.004% BAK preserved. |